Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: erlotinib hydrochloride|DRUG: letrozole|GENETIC: fluorescence in situ hybridization|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis
Sponsor: Vanderbilt-Ingram Cancer Center
Collaborators: National Cancer Institute (NCI)